BioXcel Therapeutics Inc Stock Research

Market Summary

USD18.70+0.76

Delayedas of 01 Jun 2023, 11:12 am

4.24%

BTAI Alerts

2 major insider sales recently.

BTAI Stock Price

BTAI RSI Chart

BTAI Valuation

Market Cap

522.1M

Price/Earnings (Trailing)

-2.79

Price/Sales (Trailing)

673.91

Price/Free Cashflow

-3.36

BTAI Price/Sales (Trailing)

BTAI Profitability

Return on Equity

-107.94%

Return on Assets

-55.99%

Free Cashflow Yield

-29.77%

BTAI Fundamentals

BTAI Revenue

Revenue (TTM)

774.7K

BTAI Earnings

Earnings (TTM)

-187.1M

Earnings Y/Y

-67.76%

Earnings Q/Q

3.67%

Price Action

52 Week Range

8.8034.13

(Low)(High)

Last 7 days

-30.8%

Last 30 days

-13.8%

Last 90 days

-40.1%

Trailing 12 Months

53.3%

BTAI Financial Health

Current Ratio

10.34

BTAI Investor Care

Shares Dilution (1Y)

4.00%

Diluted EPS (TTM)

-6.64

Peers (Alternatives to BioXcel Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	117.9B	26.2B	-7.64%	-12.03%	14.89	4.5	-0.48%	38.34%
GILD	96.0B	27.0B	-5.50%	23.66%	17.2	3.55	-1.56%	23.65%
MRNA	49.0B	15.1B	-4.27%	-12.12%	10.25	3.26	-33.37%	-67.32%
BIIB	42.8B	10.1B	-4.73%	48.21%	13.67	4.24	-6.61%	115.98%
MID-CAP
NBIX	8.7B	1.6B	-13.93%	-4.24%	136.39	5.46	32.38%	-10.36%
DNLI	4.1B	-	17.13%	24.41%	-11.15	38.1	122.90%	-29.67%
BEAM	2.4B	76.7M	3.81%	-9.32%	-7.51	30.96	41.73%	-32.75%
BBIO	2.2B	107.9M	-4.32%	100.88%	-4.54	20.39	54.84%	17.36%
SMALL-CAP
RCUS	1.5B	119.0M	11.39%	8.39%	-5.38	12.62	-69.61%	-584.39%
REPL	1.1B	10.0M	8.51%	30.70%	-6.18	107.56	215.65%	-47.65%
NVAX	694.6M	-	4.27%	-85.45%	-0.6	0.35	72.89%	12.32%
FATE	495.9M	136.9M	-20.60%	-78.14%	-2.11	3.62	116.83%	-0.93%
SGMO	186.8M	241.0M	-25.83%	-69.32%	-1.47	0.78	113.96%	27.87%
VXRT	165.4M	697.0K	50.34%	-66.48%	-1.53	237.34	47.98%	-35.48%
IBIO	8.7M	-	-35.78%	-88.38%	-0.11	3.21	0.51%	-129.47%

Financials for BioXcel Therapeutics

* denotes actual numbers (not divided by Thousands)
Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3
Revenue	106.6%	775	375	548	-	-
S&GA Expenses	15.9%	79,695	68,761	61,963	-	-
R&D Expenses	9.9%	100,227	91,239	71,052	-	-
Interest Expenses	20.6%	9,906	8,213	-	-	-
Net Income	-12.9%	-187,081	-165,757	-137,074	-	-
Net Income Margin	-	-250.14*	-	-	-	-
Free Cahsflow	-	-116,785	-	-	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-12.5%	180	206	245	248	211
Current Assets	-12.6%	177	203	242	245	208
Cash Equivalents	-14.6%	166	194	232	233	200
Inventory	-1.7%	2.00	2.00	1.00	1.00	1.00
Net PPE	-7.4%	1.00	1.00	1.00	1.00	1.00
Liabilities	-1.5%	127	129	118	84.00	17.00
Current Liabilities	-12.6%	29.00	33.00	23.00	20.00	16.00
LT Debt, Non Current	2.2%	95.00	93.00	92.00	61.00	-
Shareholder's Equity	-31.0%	53.00	77.00	127	164	194
Retained Earnings	-12.8%	-464	-411	-356	-314	-277
Additional Paid-In Capital	5.9%	517	488	484	479	471
Shares Outstanding	3.4%	29.00	28.00	28.00	28.00	28.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-14.7%	-155	-135	-116	-105	-94.93
Share Based Compensation	6.1%	18.00	17.00	15.00	15.00	18.00
Cashflow From Investing	7.9%	-0.14	-0.15	-0.17	-0.25	-
Cashflow From Financing	-24.8%	72.00	96.00	60.00	0.00	-

Risks for BTAI

What is the probability of a big loss on BTAI?

100%

Probability that BioXcel Therapeutics stock will be more than 20% underwater in next one year

100%

Probability that BioXcel Therapeutics stock will be more than 30% underwater in next one year.

92.3%

Probability that BioXcel Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BTAI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BioXcel Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for BTAI

Cumulative Returns on BTAI

10.0%

5-Year Cumulative Returns

-27.2%

3-Year Cumulative Returns

What are the long-term rolling returns for BTAI?

FIve years rolling returns for BioXcel Therapeutics.

Annualized Returns

Which funds bought or sold BTAI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-18	JPMORGAN CHASE & CO	added	49.12	73,000	322,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-5.93	-46,000	203,000	-%
2023-05-17	Advisory Services Network, LLC	unchanged	-	-1,077	7,128	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	206	722,025	1,156,560	-%
2023-05-16	JANE STREET GROUP, LLC	new	-	199,886	199,886	-%
2023-05-16	Rockefeller Capital Management L.P.	sold off	-100	-19,000	-	-%
2023-05-15	Legal & General Group Plc	added	2.11	-23,485	184,398	-%
2023-05-15	Metropolitan Life Insurance Co/NY	reduced	-22.22	-9,091	18,940	-%
2023-05-15	NORTHERN TRUST CORP	reduced	-1.86	-683,095	3,949,670	-%
2023-05-15	UBS ASSET MANAGEMENT AMERICAS INC	sold off	-100	-294,405	-	-%

Latest Funds Activity

Are funds buying BTAI calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BTAI

No. of Funds

BTAI Alerts

2 major insider sales recently.

BioXcel Therapeutics News

Schedule 13G FIlings of BioXcel Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 04, 2023	bioxcel holdings, inc.	29.5%	8,546,750	SC 13G/A
Feb 14, 2023	bioxcel holdings, inc.	30.5%	8,546,750	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	0.1%	24,000	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	blackrock inc.	4.7%	1,312,403	SC 13G/A
Feb 03, 2023	blackrock inc.	5.2%	1,462,922	SC 13G
Feb 02, 2023	adage capital partners gp, l.l.c.	5.53%	1,548,591	SC 13G
Feb 14, 2022	alliancebernstein l.p.	5.4%	1,508,768	SC 13G
Feb 14, 2022	bioxcel holdings, inc.	30.5%	8,546,750	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A

BTAI Fair Value

Show Fair-Value

Recent SEC filings of BioXcel Therapeutics

View All Filings

Date Filed	Form Type	Document
May 24, 2023	4	Insider Trading
May 22, 2023	144	Notice of Insider Sale Intent
May 17, 2023	DEF 14A	DEF 14A
May 16, 2023	144/A	144/A
May 16, 2023	4	Insider Trading
May 16, 2023	4	Insider Trading
May 16, 2023	4	Insider Trading
May 15, 2023	144	Notice of Insider Sale Intent
May 15, 2023	144	Notice of Insider Sale Intent
May 09, 2023	10-Q	Quarterly Report

Latest Insider Trading transactions for BTAI

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-22	Mehta Vimal	sold	-167,641	25.7909	-6,500	ceo and president
2023-05-15	Rodriguez Javier	sold	-48,764	27.3192	-1,785	see remarks
2023-05-15	Steinhart Richard I	sold	-135,864	27.1727	-5,000	chief financial officer
2023-05-14	Steinhart Richard I	acquired	-	-	5,000	chief financial officer
2023-05-14	Rodriguez Javier	acquired	-	-	5,000	see remarks
2023-05-14	Mehta Vimal	acquired	-	-	15,000	ceo and president
2023-04-06	Nandabalan Krishnan	sold	-1,039,200	17.32	-60,000	-
2023-04-06	Nandabalan Krishnan	acquired	24,600	0.41	60,000	-
2023-03-21	Mehta Vimal	sold	-591,405	19.7135	-30,000	ceo and president
2023-03-21	Mehta Vimal	acquired	12,300	0.41	30,000	ceo and president

About BioXcel Therapeutics

Vimal D. Mehta

N/A

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Income Statement

2023-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Product revenue, net	$ 206
Operating expenses
Cost of goods sold	9
Research and development	27,800	$ 18,559
Selling, general and administrative	23,595	12,921
Total operating expenses	51,404	31,480
Loss from operations	(51,198)	(31,480)
Other expense (income)
Interest expense	3,367	7
Interest income	(2,015)	(15)
Other expense, net	246
Net loss	$ (52,796)	$ (31,472)
Basic net loss per share attributable to common stockholders (in dollars per share)	$ (1.84)	$ (1.12)
Diluted net loss per share attributable to common stockholders (in dollars per share)	$ (1.84)	$ (1.12)
Weighted average shares outstanding - basic	28,616,000	27,980,000
Weighted average shares outstanding - diluted	28,616	27,980

BTAI Balance Sheet

2023-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 165,521	$ 193,725
Accounts receivable, net	283	248
Inventory	1,952	1,985
Prepaid expenses	4,506	3,067
Other current assets	5,006	3,843
Total current assets	177,268	202,868
Property and equipment, net	1,004	1,084
Operating lease right-of-use assets	906	976
Other assets	925	925
Total assets	180,103	205,853
Current liabilities
Accounts payable	7,742	10,228
Accrued expenses	17,065	18,669
Due to related parties	380	422
Accrued interest	3,088	3,175
Other current liabilities	484	404
Total current liabilities	28,759	32,898
Long-term portion of operating lease liabilities	703	786
Derivative liabilities	2,574	2,343
Long-term debt	95,062	93,051
Total liabilities	127,098	129,078
Commitments and contingencies (Note 15)
Stockholders' equity
Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of March 31, 2023 and December 31, 2022
Common stock, $0.001 par value, 100,000 shares authorized as of March 31, 2023 and December 31, 2022; 29,100 and 28,147 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	29	28
Additional paid-in-capital	517,317	488,292
Accumulated deficit	(464,341)	(411,545)
Total stockholders' equity	53,005	76,775
Total liabilities and stockholders' equity	$ 180,103	$ 205,853